Group items tagged

A new report from the Association of the British Pharmaceutical Industry (ABPI) has highlighted that while the NHS has made significant progress in the introduction of cell and gene therapies, the health service must "do more to get ready for the arrival of the advanced therapies of the future." The ABPI noted that advanced therapies, also known as Advanced Therapy Medicinal Products (ATMPs), offer hope for diseases previously deemed "untreatable." ATMPs have already been introduced for treating some rarer conditions, including haemophilia, spinal muscular atrophy, and a rare disease that causes blindness. "In some cases, these therapies can transform people's lives with just a single treatment," the Association said. The ABPI's report, titled Unlocking Access to Future ATMPs in the UK: Comparing International Approaches, emphasises the need for the NHS to revise its payment strategies for upcoming therapies.

A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.